Medicare AdvantageCoverageMedium impact
MA08.009w, Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG)
Independence Blue Cross·Allergy & Immunology, Hematology, Oncology +2 more·Medical Policy
Effective date
Jan 1, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.009w for Immune Globulin Intravenous (IVIG) and Subcutaneous (SCIG) treatments has been updated effective January 1, 2025. This policy affects billing and coverage requirements for immunoglobulin therapies under Medicare Advantage plans.
Action Required
Immediately: Billing team should review the complete policy details at the source URL to understand specific changes to IVIG/SCIG coverage and billing requirements. Update billing procedures and prior authorization workflows for immunoglobulin treatments under Medicare Advantage plans according to the new policy guidelines.